View Older Stories View More Recent Stories

Dec 20, 2018 04:15PM Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Dec 20, 2018 06:31AM Merck (MRK) Reports LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Dec 20, 2018 06:30AM LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Dec 19, 2018 04:13PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Dec 19, 2018 04:04PM AstraZeneca (AZN) and Merck (MRK) Reports LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
Dec 19, 2018 03:18PM Merck (MRK) Announces LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Dec 19, 2018 03:16PM LYNPARZA® (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Dec 17, 2018 06:31AM Merck (MRK) Announces EC Approves its KEYTRUDA as Adjuvant Therapy for Adults with Resected Stage III Melanoma
Dec 17, 2018 06:30AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma
Dec 14, 2018 06:46AM Merck (MRK) to Acquire Antelliq Group for EUR2.1 Billion Plus Debt
Dec 14, 2018 06:45AM Merck to Acquire Privately Held Antelliq Group
Dec 12, 2018 10:30AM Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections
Dec 10, 2018 04:30PM Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer
Dec 10, 2018 11:30AM MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
Dec 3, 2018 06:45AM Merck to Present at the Citi 2018 Global Healthcare Conference
Nov 28, 2018 04:32PM Merck (MRK) says EC Approved DELSTRIGO and PIFELTRO for Treatment of HIV-1 Infection
Nov 28, 2018 04:30PM European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravir
Nov 27, 2018 08:00AM MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018
Nov 19, 2018 07:12AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Nov 15, 2018 09:01AM NewLink Genetics (NLNK) Says Merck (MRK) Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 to FDA
Nov 14, 2018 06:51AM Merck (MRK) Reports Phase 3 KEYNOTE-181 Trial Investigating KEYTRUDA Met a Primary Endpoint of OS in Patients Whose Tumors Express PD-L1
Nov 14, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expre
Nov 13, 2018 04:36PM Merck (MRK) Begins Rolling Submission of Licensure Application for V920 to FDA
Nov 13, 2018 04:35PM Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Nov 12, 2018 06:56AM Merck (MRK) Says FDA Accepted Regulatory Submission for LYNPARZA Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Nov 12, 2018 06:55AM FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Nov 9, 2018 04:22PM Merck (MRK) Announces FDA Approval of KEYTRUDA for Treatment of Patients with HCC Who Have Been Previously Treated with Sorafenib
Nov 9, 2018 04:21PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
Nov 9, 2018 06:47AM Eisai and Merck (MRK) Announces New Data from Study of LENVIMA and KEYTRUDA Combination in Three Different Tumor Types
Nov 9, 2018 06:45AM New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd An
Nov 7, 2018 06:55AM Merck (MRK) Says Early Phase 1 Data from Oncology Pipeline for Investigational Anti-LAG-3 Therapy and Anti-TIGIT Therapy to Be Presented at SITC
Nov 7, 2018 06:45AM Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting
Nov 5, 2018 10:00AM MilliporeSigma Launches BioContinuum™ Platform for Next-Generation Process Improvements
Nov 1, 2018 07:11AM From pharma to prisons, election-sensitive stocks that could swing
Oct 30, 2018 05:01PM Merck (MRK) Says FDA Approved its KEYTRUDA in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for Patients with NSCLC
Oct 30, 2018 04:09PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Ce
Oct 25, 2018 06:46AM Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization
Oct 25, 2018 06:45AM Merck Announces Third-Quarter 2018 Financial Results
Oct 22, 2018 10:31AM Merck (MRK) Says KEYTRUDA Significantly Improved OS Compared to Standard of Care in Patients with Recurrent or Metastatic Head and Neck Cancer
Oct 22, 2018 10:30AM Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with
Oct 22, 2018 06:48AM Merck (MRK) Says EMA Adopts Positive Opinion for its KEYTRUDA as Adjuvant Therapy in Melanoma
Oct 22, 2018 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma
Oct 22, 2018 06:12AM Merck (MRK) Presents Early Data for Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Oct 22, 2018 05:47AM AstraZeneca (AZN), Merck (MRK) Report Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70%
Oct 21, 2018 10:30AM SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian C
Oct 20, 2018 09:00AM First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Oct 20, 2018 03:15AM Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
Oct 18, 2018 07:01AM Merck (MRK) Reports Significant Improved OS & PFS Data from Pivotal Phase 3 KEYNOTE-426 Trial Investigating KEYTRUDA (pembrolizumab) in Combination with Pfizer’s (PFE) Inlyta (axitinib)
Oct 18, 2018 06:57AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advan
Oct 17, 2018 06:45AM Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer
View More Recent Stories View Older Stories